News
VSTM
3.290
-3.80%
-0.130
Verastem (VSTM) Begins Dosing in Solid Tumors Study in China
NASDAQ · 3d ago
Weekly Report: what happened at VSTM last week (0708-0712)?
Weekly Report · 4d ago
Verastem spikes as dosing for lead program starts in China
Verastem spikes as dosing for lead program starts in China. The cancer drug developer said that dosing in a Phase 1/2 trial for its lead program, GFH375/VS-7375, has started in China by its partner. Shares of Verastem Oncology traded higher on Friday.
Seeking Alpha · 6d ago
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
ASP Isotopes Inc. Shares fell 9.2% to $3.2308 on Friday. The company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. Vicinity Motor Corp. Shares jumped 133.2%. Other stocks moving in today's mid-day session.
Benzinga · 6d ago
VERASTEM INC: TO INITIATE DEVELOPMENT STUDIES OUTSIDE OF CHINA AFTER EVALUATING INITIAL DOSE ESCALATION DATA FROM PHASE 1 STUDY IN CHINA
Reuters · 07/12 11:30
VERASTEM ONCOLOGY ANNOUNCES FIRST PATIENT DOSED WITH GFH375/VS-7375, A KRAS G12D (ON/OFF) INHIBITOR, IN A PHASE 1/2 TRIAL IN CHINA AS PART OF COLLABORATION WITH GENFLEET THERAPEUTICS
Reuters · 07/12 11:30
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)
TipRanks · 07/09 14:03
Verastem Price Target Cut to $18.00/Share From $34.00 by Truist Securities
Dow Jones · 07/08 15:53
Verastem Is Maintained at Buy by Truist Securities
Dow Jones · 07/08 15:53
Truist Securities Maintains Buy on Verastem, Lowers Price Target to $18
Benzinga · 07/08 15:43
Weekly Report: what happened at VSTM last week (0701-0705)?
Weekly Report · 07/08 11:35
VERASTEM ONCOLOGY ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 07/08 11:30
U.S. RESEARCH ROUNDUP-Acelyrin, Blue Owl Capital, Malibu Boats
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Acelyrin, Blue Owl Capital, Malibu Boats and AIG among companies with revised targets. AIG, B&G Foods, Ball and Berkshire Hathaway among those with new targets.
Reuters · 07/08 06:48
VERASTEM INC <VSTM.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $18 FROM $34
Reuters · 07/08 02:53
Weekly Report: what happened at VSTM last week (0624-0628)?
Weekly Report · 07/01 11:35
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
Verastem Oncology will be added to the Russell 3000 and Russell Microcap Indexes effective Monday, July 1, 2024. The company is a biopharmaceutical company committed to advancing new medicines for patients with cancer. The Russell U.S. Indexes annual reconstitution captures the 4,000 largest stocks in the United States.
Barchart · 07/01 06:30
Verastem Updates Corporate Presentation with Latest Insights
TipRanks · 06/26 11:29
Weekly Report: what happened at VSTM last week (0617-0621)?
Weekly Report · 06/24 11:44
Reported Wednesday, China's NMPA Approves GenFleet And Verastem Oncology's GFH375 For KRAS G12D Phase I/II Trials
China's National Medical Products Administration approves clinical trial application for GFH375. GenFleet Therapeutics is a clinical-stage biotechnology company focusing on oncology and immunology. The drug targets advanced solid tumor patients with KRAS G12D mutation. G12d mutation is the most prevalent KRAS mutation in human cancers.
Benzinga · 06/20 09:45
Weekly Report: what happened at VSTM last week (0610-0614)?
Weekly Report · 06/17 11:34
More
Webull provides a variety of real-time VSTM stock news. You can receive the latest news about Verastem through multiple platforms. This information may help you make smarter investment decisions.
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).